,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'breast']
 excellent presentation on safety update of destiny breast 03 study. reinforces established favorable risk/benefit profile of tdxd over tdm-1 in her2 mbc. #asco22 